Sensible combines biotechnology, computational modelling and artificial intelligence, paving the way for a new generation of mRNA therapeutics for cancer, genetic disorders and a range of other serious diseases. The company works with global technology leaders, leveraging their computing technologies and AI to reduce one of its mRNA optimisation cycles from 15 days to just one.
Beyond enabling the development of next-generation therapeutics, Sensible’s technology is designed to enable local, flexible and resilient mRNA manufacturing. In doing so, it can help strengthen manufacturing capacity in Europe and the United States, while improving the ability to respond rapidly to emerging biological threats.
Sensible Biotechnologies has secured a total of $47 million to further develop its integrated mRNA technology and expand its applications. The financing includes a Series A round led by Oxford Science Enterprises and up to $20 million in public funding from the Slovak government and the European Union. Tech Horizons participated in the investment round alongside OTB Ventures, In-Q-Tel and existing investors Recode Ventures, Isomer Capital, Y Combinator, Backed VC, Kaya VC, Civilization Ventures and BlueYard Capital. Investors also include the family office of BioNTech co-founder Christoph Huber and Tim Garnett, former Chief Medical Officer of Eli Lilly. Previous investors include other European early-stage venture capital funds such as ZAKA VC, Amino Collective and Possible Ventures.
“Sensible Biotechnologies stood out to us above all because of its exceptional founding team and a technology that fundamentally changes the way mRNA is manufactured. Instead of costly synthesis in a test tube, it uses engineered cells as factories to produce significantly purer mRNA. This technology has strategic importance for Europe: it opens a path towards greater self-sufficiency in manufacturing next-generation medicines for devastating diseases such as cancer. Sensible Biotechnologies reduces dependence on a narrow group of suppliers and strengthens biosecurity across the region. Resilient biotechnology supply chains are now just as critical to Europe’s security as the defence industry, and we are proud to support Miroslav Gašpárek and his team on this journey.”
Matej Luhový | Partner, Tech Horizons
Sensible takes a different approach by manufacturing mRNA directly inside living cells. Its VECTOR™ platform combines computational modelling, AI-based sequence optimisation, rapid testing of large numbers of variants, and proprietary genetically engineered eukaryotic cells. The result is naturally modified mRNA – meaning that the mRNA undergoes natural modifications within the cell as it is produced. Sensible then uses its PromPT™ technology to capture and protect the mRNA inside the cells until it is isolated and further processed for use in therapeutics.
By harnessing the natural mechanisms of living cells, Sensible’s platform can produce mRNA with lower immunogenicity – meaning a lower risk of an unwanted immune response – while maintaining a high capacity to produce the desired proteins. mRNA essentially acts as a set of instructions that tells cells how to make specific proteins required to achieve the intended therapeutic effect. The technology also avoids contamination with double-stranded RNA (dsRNA), one of the main triggers of unwanted immune-system activation. The platform further reduces dependence on the complex and costly supply chains for raw materials required by conventional cell-free mRNA manufacturing.
“mRNA has already transformed the field of vaccines, but we believe its greatest potential is still ahead of us – both in the development of new therapeutics and in our ability to respond rapidly to emerging biological threats. Sensible is developing an entirely new, cell-based approach to mRNA design and manufacturing that combines high-quality mRNA with production that can be efficiently scaled and is more resilient to supply-chain disruptions. We are delighted to have the support of Tech Horizons in our next phase of growth, particularly given its focus on technologies that strengthen Western resilience and security. Our ambition is not only to enable a new generation of mRNA therapeutics for diseases such as cancer and currently incurable genetic disorders, but also to help build the biotechnology manufacturing capacity that Europe, NATO and their allies will increasingly need to protect public health and strengthen their strategic resilience.”
Miroslav Gašpárek | Co-Founder and CEO of Sensible Biotechnologies
Sensible will use the new funding to further develop its platform, expand manufacturing and automate laboratory and production processes. The company operates laboratories in Oxford and Bratislava and has secured access to a modern cGMP manufacturing facility in eastern Slovakia, which meets stringent standards for pharmaceutical manufacturing.
In partnership with Sartorius, Sensible is building capacity to manufacture mRNA at the quality required for clinical use. It also collaborates with leading global technology companies and world-class academic laboratories. Sensible’s technology for the cell-based manufacturing of circular RNA, a specific type of RNA with a circular structure, has also been published in the scientific journals Nature Biotechnology and Cell Chemical Biology.
From next-generation therapeutics to European biosecurity
Sensible’s technology also has broader implications for biosecurity and Europe’s strategic resilience. The ability to rapidly design, optimise and subsequently manufacture mRNA could shorten the time required to develop medical countermeasures against emerging biological threats.
The company has already received support from NATO DIANA, the Slovak government, the European Union (through designation as an Important Project of Common European Interest) and Germany’s Federal Agency for Disruptive Innovation, SPRIN-D. Enabling manufacturing capability in both Europe and the United States is an important part of Sensible’s vision.
Sensible is already validating its technology in collaboration with pharmaceutical and biotechnology companies. Its platform has demonstrated both the ability to manufacture mRNA directly inside cells without contamination by double-stranded RNA (dsRNA), and lower mRNA immunogenicity – meaning a lower risk of an unwanted immune response – compared with conventional manufacturing methods. Sensible has also developed a system capable of testing hundreds of different mRNA sequences in a single cycle.
The company’s long-term goal is to use the platform to develop a new generation of mRNA therapeutics. Potential applications range from cancer and genetic diseases to protein replacement and cell therapies.
“Biotechnology and biomanufacturing are playing an increasingly important role in national and economic security. Sensible Biotechnologies is developing a new approach to mRNA design and manufacturing that has the potential to improve its properties while strengthening the resilience of this critical technology. We are pleased to support Sensible as it continues to develop its platform and explore its potential across next-generation therapeutics, decentralised mRNA manufacturing and preparedness for biological threats.”
J. D. Englehart | Senior Investment Director at In-Q-Tel and Board Observer at Sensible